Health News-RSS Feeds

Subscribe to Health News-RSS Feeds feed Health News-RSS Feeds
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals.
Updated: 18 min 13 sec ago

CMS to cover Abbott's glucose monitoring device

January 4, 2018 - 10:12pm
(Reuters) - Abbott Laboratories said on Thursday its newly launched glucose monitoring device would be covered by the Centers for Medicare & Medicaid Services, expanding its usage to millions of diabetes patients in the United States.

British PM May apologizes as overwhelmed hospitals cancel non-emergency operations

January 4, 2018 - 8:57pm
LONDON (Reuters) - Britain's Prime Minister Theresa May apologized on Thursday to tens of thousands of patients whose operations were canceled to free up staff and beds to deal with emergency patients.

Trump administration to end Obama-era marijuana policy: source

January 4, 2018 - 8:09pm
WASHINGTON (Reuters) - The U.S. Department of Justice on Thursday will rescind an earlier marijuana policy under former Democratic President Barack Obama that eased enforcement of federal laws amid a growing number of local legalization efforts, according to a source familiar with the change.

Zambia shuts Hungry Lion restaurants over cholera contamination

January 4, 2018 - 7:52pm
LUSAKA (Reuters) - Zambia has shut three of South African retailer Shoprite's Hungry Lion fast-food restaurants after their food tested positive for the bacterium that causes cholera, a government minister said on Thursday.

Suspected diphtheria cases in Yemen near 500: WHO

January 4, 2018 - 6:00pm
GENEVA (Reuters) - At least 471 people in Yemen are believed to have been infected with diphtheria, killing one in 10 of them since the outbreak began in mid-August, the World Health Organization (WHO) said on Thursday.

Philippines fines Sanofi, suspends clearance for Dengvaxia

January 4, 2018 - 5:30pm
MANILA (Reuters) - The Philippines has suspended clearance for Sanofi's dengue vaccine Dengvaxia and fined the French drugmaker a symbolic $2,000 citing violations on product registration and marketing, the health secretary said on Thursday.

Novartis' Promacta receives FDA breakthrough designation for new indication

January 4, 2018 - 12:23pm
ZURICH (Reuters) - Novartis drug Promacta has received breakthrough therapy designation from the U.S. Food and Drug Administration for first-line treatment of severe aplastic anemia (SAA).

Philippines fines Sanofi, suspends clearance for Dengvaxia

January 4, 2018 - 11:38am
MANILA (Reuters) - The Philippines has fined Sanofi $2,000 and suspended clearance for the French drug maker's controversial dengue vaccine Dengvaxia, citing violations on product registration and marketing, its health secretary said on Thursday.

Australia to permit medicinal cannabis exports in bid to capture lucrative market

January 4, 2018 - 9:35am
SYDNEY (Reuters) - Australia said Thursday it planned to become the fourth country in the world to legalize medicinal marijuana exports in a bid to score a piece of the estimated $55 billion global market.

Monsanto wins support from 11 U.S. states in California cancer dispute

January 4, 2018 - 5:16am
CHICAGO (Reuters) - Monsanto Co has won support from eleven U.S. states in its attempt to stop California from requiring cancer warnings on products containing glyphosate, ratcheting up a legal fight over the company's popular weed killer.

Air pollution around conception tied to birth defects

January 4, 2018 - 5:14am
(Reuters Health) - - Women who breathe polluted air during the month right before or after they get pregnant may be more likely to have babies with birth defects, a U.S. recent study suggests.

Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

January 4, 2018 - 4:13am
(Reuters) - Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.

Heart benefit of moderate drinking greater in wealthy people

January 4, 2018 - 3:29am
(Reuters Health) - - People who enjoy a few cocktails each week may be less likely to die from heart disease than people who rarely or never drink, especially if they’re rich, a Norwegian study suggests.

Click bait ads are tied to teen smoking

January 4, 2018 - 2:23am
(Reuters Health) - - Teens who engage with online tobacco ads are more likely to start smoking than their peers who aren’t lured by digital marketing campaigns, a U.S. study suggests.

FDA issues recall on J&J heart device

January 4, 2018 - 1:14am
(Reuters) - The U.S. Food and Drug Administration on Tuesday issued a recall of a heart device made by a unit of Johnson & Johnson due to a faulty valve, following a recall by the company in June.

Immune boosting virus could be used to treat brain tumors

January 4, 2018 - 12:31am
LONDON (Reuters) - A trial of a potential new brain cancer treatment has shown that a virus injected directly into the bloodstream can reach tumors deep inside the brain and switch on the body's own defense system to attack them.

How alcohol damages stem cell DNA and increases cancer risk

January 4, 2018 - 12:00am
LONDON (Reuters) - Drinking alcohol produces a harmful chemical in the body which can lead to permanent genetic damage in the DNA of stem cells, increasing the risk of cancer developing, according to research published on Wednesday.

Age may be a factor in facial skin cancer treatment

January 3, 2018 - 11:29pm
(Reuters Health) – - In very elderly patients, less aggressive skin cancers on the face might not always need to be treated, a new study suggests.

Spark to charge $850,000 per patient for blindness gene therapy

January 3, 2018 - 8:52pm
(Reuters) - Spark Therapeutics Inc said on Wednesday it will charge $850,000 per patient for its breakthrough gene therapy to treat a rare form of blindness, a lower than expected price that the company said reflects patient and insurer concerns about access and cost.

Spark Therapeutics' vision-loss gene therapy to cost $850,000 per patient

January 3, 2018 - 8:06pm
(Reuters) - Spark Therapeutics Inc said on Wednesday it would charge $850,000 per patient for its gene therapy to treat a rare form of blindness, lesser than analysts' expectation of around $1 million.